ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, confirmed that it has received an unsolicited preliminary non-binding proposal from Claritas Capital to acquire all of the outstanding shares of common stock of the Company, not already beneficially owned by Claritas and its affiliated funds, for cash consideration of between $1.35 and $1.80 per share. Consistent with its fiduciary duties, the Company's Board of Directors will carefully review Claritas’ proposal with the Board’s advisors and pursue the course of action it determines to be in the best interests of the Company and all of its stockholders.
Sharecare stockholders do not need to take any action at this time. There is no certainty that any transaction will be consummated, and Sharecare does not intend to comment further unless it determines that additional disclosure is appropriate. The proposal was required to be disclosed by Claritas under Regulation 13D by the U.S. Securities and Exchange Commission.
About Sharecare
Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.
Media Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.43 |
Daily Volume: | 0 |
Market Cap: | US$531.790M |
September 10, 2024 August 09, 2024 March 28, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load